The Legendary Debate

The Investment Decision Council: Novo Nordisk (NVO)

Phase 1: Business Quality & Long-Term Moat

Warren Buffett: sets down his reading glasses "Healthcare is tricky — you need both scientific genius and business discipline. I want to start with the simplest question I can think of: if a patient walks into a doctor's office today weighing 250 pounds with a hemoglobin A1c of 8.5, is the doctor reaching for a Novo Nordisk product? And will that doctor still be reaching for a Novo Nordisk product in 2035? Because that's really the whole ballgame. Not the pipeline, not CagriSema, not the stock price — just whether the reflexive clinical choice still belongs to this company."

Charlie Munger: "Let me invert that, as I always do. What kills this business? Three things could do it: a competitor creates a molecule so dramatically superior that the switching costs — which are real, because patients on semaglutide who stop gain the weight back and must retitrate — no longer matter. Second, a small-molecule oral pill achieves the same efficacy as these biologic injectables, which would render those multibillion-dollar fermentation facilities about as useful as a Kodak film plant. And third — the one nobody in this room wants to talk about — payers simply refuse to cover these drugs at current prices, and the self-pay market proves far more elastic than the 120,000 weekly prescriptions currently suggest. Now, the first scenario is partially happening with Lilly's tirzepatide delivering 20-25% weight loss versus semaglutide's 15-17%. The second is plausible but years away. The third is the one management tiptoed around on the earnings call when they mentioned states dropping Medicaid coverage and 'lower realized prices.' That language doesn't come from a position of strength."

Dev Kantesaria: "Charlie, I want to engage honestly with your framework, but I have to be transparent about my priors. Despite my medical degree — indeed, because of it — I categorically avoid healthcare and pharma. I studied medicine at Harvard, and the single most important lesson I took away is that clinical outcomes over five-to-ten year horizons are not predictable by anyone, no matter how brilliant. The semaglutide story proves it perfectly: five years ago this molecule was an uncontested monopoly. Three years ago, tirzepatide emerged with clinically superior weight loss. Today there are over 100 GLP-1 and related molecules in development. Compare this to my actual holdings — every mortgage in America requires a FICO score, every bond requires a Moody's rating, every electronic transaction pays Visa's toll. Those are inevitabilities. A physician's prescription is a choice, and choices can shift with a single trial readout. I admire the economics enormously — 82% gross margins are breathtaking — but I need inevitability, not probability, and pharmaceutical markets cannot provide that."

David Tepper: "Dev, I respect your framework, but you're conflating two different things. You're right that individual molecule dominance is unpredictable. But the question isn't whether semaglutide specifically dominates in 2035 — it's whether Novo Nordisk as an institution keeps generating the next molecule. And here the track record is a century long. They pivoted from animal insulin to recombinant human insulin in the 1980s. They pivoted from insulin to GLP-1 agonists in the 2010s. They've already filed CagriSema, which showed 14.2% weight loss superior to semaglutide alone in the REIMAGINE 2 trial, and zenagamtide demonstrated 22% weight loss in early studies — potentially matching or exceeding tirzepatide. No other company in this space has three product generations simultaneously in late-stage development. The pipeline IS the moat, not any single molecule."

Pulak Prasad: "David, I hear your argument, but you're describing a business that survives through constant reinvention. That's precisely what concerns me from a Darwinian perspective. My preferred investments — think of Asian Paints in India, or Nestlé — operate in environments where the competitive landscape evolves over decades, not years. Novo Nordisk's GLP-1 market went from a one-player monopoly to a two-player duopoly in three years, and it's heading toward five-to-seven players by 2030. That rate of competitive evolution means that every single year, management must make R&D bets worth billions on molecules whose clinical outcomes are fundamentally uncertain. Some years they'll be right. Some years they won't. And the balance sheet — which went from DKK 27 billion in debt to DKK 131 billion in just two years — tells me management is doubling down on the current competitive position at precisely the moment when the competitive field is broadening. That's an organism consuming its reserves to fight a battle whose outcome is uncertain."

Robert Vinall: "Pulak, I share some of your concern about the pace of change, but I want to push back on the balance sheet point. The debt isn't defensive spending — it funded the Catalent manufacturing acquisitions and new biologic fermentation capacity. In a market where demand still exceeds supply for key products, manufacturing capacity IS the competitive weapon. No competitor can replicate that capacity for three to five years regardless of their molecule quality. And here's what's fascinating: Novo Nordisk just launched the Wegovy pill — the first oral GLP-1 peptide for obesity — and it generated 50,000 weekly prescriptions within three weeks. Management said the uptake was 'over twice that of any prior anti-obesity drug launch,' and critically, most prescriptions were for patients new to these medications. That's not share-stealing from Lilly. That's market creation. The moat might be narrowing in injectable form factors, but the Wegovy pill suggests the franchise can still widen the overall market."

Mohnish Pabrai: "Robert, I find the business genuinely impressive — EPS went from $0.69 in 2012 to $3.15 in 2024, which is a beautiful compounding story. But I want to raise the uncomfortable question nobody has asked yet: the 'away from desk' test. If I buy this stock today and don't look at it for twelve months, am I confident it compounds quietly? The honest answer is no. I'd need to monitor Wegovy pill prescription trajectories, CagriSema trial readouts, Medicare coverage decisions, the REDEFINE 4 head-to-head data, and whether two brand-new C-suite executives can manage the most complex commercial launch in the company's history. That's not a business that compounds on autopilot — that's a business that requires you to watch every quarterly earnings release with your hand on the sell button. My best investments have been ones where I could go fishing for a year and the business got stronger without me watching."

Phase 2: Financial History & Long-Term Growth

Warren Buffett: "Let's bring the numbers in now, because Mohnish raises a fair point and the financials either support or undermine it. The ten-year revenue story has two very distinct chapters. From 2016 through 2019, this business was essentially stagnant — revenue flat around $16-18 billion, growth essentially zero. Then semaglutide hit its commercial stride and revenue tripled to $40 billion by 2024 with 25-31% annual growth. The question is which chapter we're entering next. Management reported 10% growth in 2025 while the GLP-1 market grew 30%. That's not stagnation, but it's a dramatic deceleration, and the share loss to Lilly is real — Dave Moore on the earnings call explicitly acknowledged 'market share losses and lower realized prices' for Ozempic."

Charlie Munger: "What concerns me more than the revenue deceleration is the ROIC trajectory, because that's where you see whether the moat is real or just a temporary competitive advantage being competed away. ROIC peaked at 83% in 2015 when this was a lean, capital-light insulin franchise. Today it's 43% and trending down. Now, 43% ROIC is still extraordinary — most businesses would kill for it — but the direction matters more than the level. The compression is entirely driven by the capital base: invested capital roughly tripled while operating profit grew more modestly. Management bet the balance sheet on manufacturing scale, and the return on that bet is the single most important variable in this investment. If the new capacity generates revenue at rates comparable to the existing asset base, ROIC recovers toward 50-60% and this was a brilliant capital allocation decision. If the capacity comes online into a market with more competitors and lower net pricing, ROIC settles at 25-30% and this becomes a very good pharmaceutical company rather than an extraordinary franchise."

David Tepper: "Charlie, you're making the bears' case elegantly, but look at the operating margins — they've held above 42% for thirteen consecutive years, through the insulin-to-GLP-1 transition, through COVID, through the current competitive intensification. That's a business where the cost structure reinforces profitability at scale. And the free cash flow picture, while volatile — DKK 65 billion in 2023, negative DKK 8 billion in 2024 as CapEx peaked, recovered to DKK 40 billion in 2025 — shows operating cash flow of DKK 119 billion flowing through reliably. The CapEx cycle caused the FCF swing, not any operating deterioration. When I see a business generating $16 billion in annual operating cash flow at 42% operating margins with a stock down 48%, my instincts tell me the market is pricing in a catastrophe that the income statement doesn't show."

Dev Kantesaria: "David, the income statement is fine — I've never disputed the current economics. What I dispute is the sustainability. You just cited thirteen years of 42% operating margins. But 2025 broke the streak with a roughly 290 basis point compression to approximately 41.3%, driven partly by restructuring charges but also by the competitive dynamics everyone in this room acknowledges. And here's the pattern I've seen in pharma repeatedly: the margins hold beautifully right up until the moment they don't, because pharmaceutical pricing is a step function, not a gradual slope. When a PBM decides to favor tirzepatide over Ozempic on a major formulary, the revenue doesn't decline 2% — it drops 15-20% in that channel overnight. That's why I can't get comfortable with these margins as permanent — they depend on formulary positioning that gets renegotiated annually."

Robert Vinall: "Dev makes a legitimate point about formulary risk, but there's a counterargument the bears consistently ignore: the self-pay channel. Management said self-pay now accounts for roughly 30% of injectable Wegovy prescriptions and approximately 90% of the Wegovy pill's early prescriptions. These are patients paying hundreds of dollars monthly out of their own pocket because the medication transforms their lives. That willingness-to-pay signal is the single strongest evidence of demand durability I've seen in any pharmaceutical business. It's analogous to what I look for in my consumer holdings — when people spend their own money despite having cheaper alternatives, the product has earned genuine loyalty. The PBM formulary war matters, but it's not the whole picture."

Phase 3: Valuation & Final Verdicts

Warren Buffett: "Let's talk price. At $36.53, the stock trades at roughly 11.6x the 2024 EPS of $3.15 per ADR from ROIC.AI. The market is pricing this as if the obesity revolution has been fully competed away and Novo Nordisk is heading back to the stagnation of 2016-2019. My blended valuation using 15-17x normalized EPS of $3.00-3.15 puts fair value around $45-52. That gives us 23-42% upside from here, with downside limited to roughly $35-38 in a bear case where margins compress and the multiple stays depressed. The asymmetry works for me. I'm a buyer at $36.53, but I'd size it at 2-3% — smaller than a typical Berkshire position — because the balance sheet transformation and leadership churn introduce more uncertainty than I'd like for a full-conviction holding."

Charlie Munger: "I end up in the same place as Warren, though I arrive there through inversion rather than valuation math. I simply cannot construct a plausible scenario where buying 82% gross margins and 42% operating margins at 11.6x earnings permanently loses money. The three kill scenarios I outlined earlier — competitive displacement, technological obsolescence, payer rebellion — are all possible but none is probable at the severity level the market is pricing. The market has extrapolated one year of relative share loss into a permanent decline narrative. I've seen this pattern before with Costco during periodic scares — the stock gets repriced as if the business model is broken, then the underlying quality reasserts itself. I'm buying at $36.53."

David Tepper: "I'm the most aggressive buyer in this room. At 11.6x trailing earnings for a business generating $16 billion in annual operating cash flow, this is the kind of setup where asymmetric returns are made. My bear case — $2.90 trough EPS at 12x — gives me $35, roughly 4% downside. My base case — $3.40 at 17x as catalysts materialize — gives me $58, or 59% upside. That's roughly 15:1 asymmetry. Five independent catalysts in the next year — Wegovy pill scaling, high-dose semaglutide FDA decision, CagriSema review, Medicare coverage, and the REDEFINE 4 head-to-head interpretation — give me multiple shots on goal. I'm sizing this at 4-5%."

Robert Vinall: "I'm a buyer but with less conviction than David. My sum-of-parts work gets me to roughly $47-53 per ADR. The 2025 FCF recovery from negative DKK 8 billion to positive DKK 40 billion addressed my primary concern about the CapEx cycle peaking. At $36.53, I can see my 15% annualized return hurdle being achieved over three years even under conservative assumptions. But the leadership transition — new CEO, two new EVPs, 9,000-person restructuring — makes me want to start at 2% and add on evidence. The institutional culture of a century-old company provides stability, but I don't have a founder-operator to anchor my conviction to, and that matters in my framework."

Dev Kantesaria: "I must be consistent with my principles. Despite the exceptional current economics, healthcare is categorically outside my investable universe. The ROIC compression from 83% to 43% over fourteen years is precisely the pattern I avoid — it demonstrates that pharmaceutical moats erode under competitive pressure in ways that my toll booth businesses do not. FICO's ROIC has been consistently above 100%. Moody's has maintained above 40% for decades without needing to quintuple its debt. I admire this business enormously, but I need inevitability, and the GLP-1 competitive landscape cannot provide it. I'm avoiding the stock."

Mohnish Pabrai: "The business quality is undeniable — I've said that clearly. But at $162 billion market cap, the math simply doesn't work for my framework. I need 3:1 upside-to-downside, meaning this stock needs to triple to roughly $110 per ADR — implying a $490 billion market cap and approximately 35x current earnings. Is that possible for the leading GLP-1 franchise in a $250 billion TAM? Mathematically yes. Probable enough for me to bet on? No. My best returns have come from $500 million to $5 billion market cap situations where a triple is plausible with normalized assumptions. I'll admire Novo Nordisk from the sidelines and wait for a market cap below $90 billion, which would mean the stock at around $20. At that price, the asymmetric math works beautifully."

Pulak Prasad: "I find myself in the minority with Dev and Mohnish, though for different reasons than either. My concern isn't the price or the category exclusion — it's the rate of competitive evolution. This market went from monopoly to duopoly in three years and will be a five-to-seven player field by 2030. The ROIC declining from 83% to 43% while the competitive field expands is the financial signature of eroding evolutionary fitness. My preferred investments operate in slow-changing environments where I can hold for two decades without monitoring competitive dynamics quarterly. Novo Nordisk requires exactly the kind of constant vigilance that Mohnish described — watching trial readouts, formulary negotiations, prescription trends every quarter. That's not how I invest."

Phase 4: Synthesis & Conclusion

Warren Buffett: surveys the room "Let me try to pull this together, because we've covered a lot of ground and the disagreements here are genuinely instructive — they're not about stubbornness but about fundamentally different frameworks confronting the same evidence.

On the qualitative side, we broadly agree that Novo Nordisk has built something remarkable over a century. The biologic manufacturing moat is real — you cannot replicate fermentation capacity in a year or five, no matter how much capital you deploy. The chronic-disease patient base of 46 million people creates the kind of recurring revenue I associate with my best long-term holdings. And the Wegovy pill launch — 50,000 prescriptions in three weeks, predominantly new patients — demonstrates this franchise can still create demand rather than merely defend it.

But this debate surfaced genuine tension. Dev and Pulak make a structural argument that I respect: pharmaceutical moats require constant reinvention through R&D, and the competitive pace in GLP-1 is far faster than in the slow-changing industries they prefer. The ROIC compression from 83% to 43% is not noise — it reflects a business model transitioning from capital-light franchise to capital-intensive manufacturer, and whether that new model earns returns consistent with the old one remains unproven. Mohnish agrees on quality but cannot make the asymmetric math work at $162 billion market cap, and that's intellectual honesty, not stubbornness.

Where Charlie, David, Robert, and I land differently is on the gap between what the market is pricing — essentially 2-3% perpetual growth for a business that has compounded at 14% — and what we believe is a more reasonable base case. The balance sheet warrants real caution: DKK 131 billion in debt where there was DKK 27 billion three years ago is not the fortress I prefer. The leadership churn is genuine execution risk. But at $36.53 — 11.6x earnings on a business with 82% gross margins, 42% operating margins, and the deepest pipeline in its industry — the market is pricing near-certainty of structural decline. We think the probability of that outcome is closer to 25-30%, not the 70-80% the multiple implies. Four of us are buyers at current prices, with David sized most aggressively and Robert most cautiously. Three of us are avoiding — Dev on category principle, Mohnish on size constraint, and Pulak on competitive evolution pace. Reasonable people, looking at the same facts, reaching different conclusions. That's exactly how it should be."